2seventy bio Inc. (TSVT): Price and Financial Metrics
GET POWR RATINGS... FREE!
TSVT Stock Price Chart Interactive Chart >
TSVT Price/Volume Stats
|Current price||$12.14||52-week high||$64.00|
|Prev. close||$11.73||52-week low||$10.57|
|Day high||$12.41||Avg. volume||453,405|
|50-day MA||$14.89||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||456.73M|
2seventy bio Inc. (TSVT) Company Bio
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Most Popular Stories View All
TSVT Latest News Stream
|Loading, please wait...|
TSVT Latest Social Stream
View Full TSVT Social Stream
Latest TSVT News From Around the Web
Below are the latest news stories about 2seventy bio Inc that investors may wish to consider to help them evaluate TSVT as an investment opportunity.
CAMBRIDGE, Mass., February 14, 2022--2seventy bio, Inc. (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the role of chief medical officer (CMO). Also announced today, Susan Abu-Absi, Ph.D. has been appointed chief technology & manufacturing officer at 2seventy bio.
CAMBRIDGE, Mass., February 14, 2022--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences:
Every investor in 2seventy bio, Inc. ( NASDAQ:TSVT ) should be aware of the most powerful shareholder groups. Generally...
Richmond, VA, based Investment company Virginia Retirement Systems Et Al (Current Portfolio) buys Wolfspeed Inc, Orion Office REIT Inc, Kyndryl Holdings Inc, 2seventy bio Inc, Loyalty Ventures Inc, sells American Water Works Co Inc, Johnson & Johnson, Activision Blizzard Inc, Intuit Inc, Dollar General Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Virginia Retirement Systems Et Al.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil
TSVT Price Returns